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ABSTRACT
Background    Some previous studies have examined 
anti-resorptive agent-related osteonecrosis of the jaw 
(ARONJ) prediction using systemic markers of bone 
turnover as risk factors. Radiographic imaging is also 
effective at detecting ARONJ. In this study, computed 
tomography (CT)-derived bone mineral density (BMD) 
values and the levels of systemic markers of bone turn-
over were evaluated, and then each parameter was com-
pared between patients that developed ARONJ and those 
who did not after treatment with systemic anti-resorptive 
agents. The aim of this study was to determine whether 
systemic markers of bone turnover and/or BMD values 
can be used to predict the risk of ARONJ.
Methods    The subjects’ serum levels of cross-linked 
N-terminal telopeptide of type I collagen (NTX) and 
bone alkaline phosphatase (BAP) (systemic markers of 
bone turnover) were measured. BMD was calibrated to 
CT values using a medical imaging phantom. Then, the 
subjects’ BMD were assessed using quantitative com-
puted tomography. Fifty-six patients who had received 
systemic anti-resorptive agents were included in this 
study. Thirty-two of the patients developed ARONJ after 
receiving the drugs whereas the remaining 24 did not. 
Results    No correlation was observed between the se-
rum levels of the systemic markers of bone turnover and 
the incidence of ARONJ. On the other hand, the ARONJ 
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patients exhibited higher mandibular BMD values than 
the control group. BMD was not associated with healing 
or the clinical stage of ARONJ.
Conclusion    These results suggest that increased 
mandibular BMD values are associated with ARONJ. 
Furthermore, mandibular BMD might serve as a novel 
marker for predicting the risk of ARONJ in patients that 
are taking anti-resorptive agents and are about to un-
dergo tooth extraction. Accordingly, mandibular BMD 
could be a useful tool for aiding risk assessments and 
guiding treatment decisions.
Key words    anti-resorptive agent-related osteonecrosis 
of the jaw; bone mineral density; quantitative computed 
tomography; systemic markers of bone turnover 
Bisphosphonates are potent inhibitors of oeoclast activ-
ity1–3 and are widely used in the clinical setting to inhibit 
osteoclast activity in malignant and benign disorders 
that are characterized by excessive bone resorption, such 
as tumor-induced osteolysis and osteoporosis.4–15 World-
wide, more than 200 million patients with common 
bone disorders are currently being treated with anti-re-
sorptive agents.16 However, the long-term administration 
of bisphosphonates adversely affects bone quality and 
metabolism. Since the first report of 3 cases of bisphos-
phonate-related osteonecrosis of the jaw (BRONJ) was 
published in 2003,17 a growing number of studies have 
examined the condition.18–22 In recent years, denosumab, 
an anti-resorptive agent with a novel mechanism of ac-
tion, has been developed, and several reports have been 
published on osteomyelitis and/or necrosis of the jaw 
associated with the use of denosumab.23–25 The receptor 
activator of nuclear factor kB ligand (RANKL) inhibitor 
is a fully humanized antibody against RANKL that acts 
an anti-resorptive agent and inhibits osteoclast activity 
and the associated bone resorption. Due to the develop-
ment of such drugs, the term BRONJ was changed to 
anti-resorptive agent-related osteonecrosis of the jaw 
(ARONJ), which encompasses the adverse effects of 
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other anti-resorptive agents. There have been a number 
of studies on the incidence of ARONJ, but no consensus 
has been reached.18, 21, 26 ARONJ is extremely intracta-
ble. In addition, there are no established therapies for the 
condition. Therefore, the prevention and early diagnosis 
of ARONJ are very important.
 The use of anti-resorptive agents significantly re-
duces the risk of fractures and skeletal-related troubles. 
In addition, it increases the bone mineral density (BMD) 
of the lumbar vertebra, etc.27 Systemic markers of bone 
turnover can provide clinically useful evidence of refl ect 
bone cell activity in the skeleton during medical treat-
ment. Such markers have gained widespread acceptance 
and are routinely used in the clinical setting. However, 
they are not currently employed in dentistry.
 Although various radiological studies of ARONJ 
have been published, patients who had been adminis-
tered anti-resorptive agents did not exhibit consistent ra-
diological jaws changes. Thus, imaging tools that could 
aid the detection of bone changes associated with anti-
resorptive agents are required.
 In this study, computed tomography (CT)-derived 
BMD values and the levels of systemic markers of bone 
turnover were evaluated, and then each parameter was 
compared between patients that developed ARONJ and 
those who did not after treatment with systemic anti-
resorptive agents.
MA TERIALS AND METHODS
Pa tients
This present study was performed with patients who 
were referred to the Division of Oral and Maxillofacial 
Biopathological Surgery, Tottori University Faculty of 
Medicine from March 2008 to August 2014. The study 
group consisted of 32 patients who had been receiving 
anti-resorptive agents (administered intravenously and 
orally in 13 and 19 cases, respectively), had undergone a 
CT scan of their mandible and had a blood test at the 
first medical examination with or without developing 
ARONJ. ARONJ was diagnosed according to the crite-
ria proposed by The American Association of Oral and 
Maxillofacial Surgeons (AAOMS) and the American 
Society for Bone and Mineral Research28: i) current 
or previous treatment with anti-resorptive agents; ii) 
exposed bone or bone that could be probed through an 
intraoral or extraoral fi stula in the maxillofacial region 
that had persisted for more than 8 weeks and iii) no his-
tory of radiotherapy involving the jaws or obvious me-
tastasis to the jaws. The criteria between the healing and 
non-healing groups were decided by the response from 
patients with conservative treatments such as antibiotic 
medication, irrigation and/or extirpation of separated 
sequester.
 The control group consisted of 24 patients who had 
a history of treatment with anti-resorptive agents, had 
never developed mandibular lesions or ARONJ, and had 
undergone a CT scan and blood sampling of their man-
dible prior to tooth extraction. In the control group, tooth 
extraction was clinically necessary in all subjects. Ap-
proval for the study was obtained from the institutional 
review board of the Faculty of Medicine, Tottori Univer-
sity.
Staging categories
ARONJ was staged according to the 2007 AAOMS 
guidelines29:
Stage 1: Exposed/necrotic bone in patients who are as-
ymptomatic and have no evidence of infection.
Stage 2: Exposed/necrotic bone in patients with pain and 
clinical evidence of infection.
Stage 3: Exposed/necrotic bone in patients with pain; in-
fection; and one or more of the following: a pathological 
fracture, extraoral fi stula, or osteolysis extending to the 
inferior border.
Blood collection and measurement of systemic 
markers of bone turnover 
We collected blood samples from each patient and 
measured the blood levels of cross-linked N-terminal 
telopeptide of type I collagen (NTX) and bone alkaline 
phosphatase (BAP).
CT and bone mineral density measurements
CT images were obtained using an Aquilion64 64-slice 
spiral CT scanner (Toshiba, Tokyo, Japan). A medical 
imaging phantom (Kyoto Kagaku, Kyoto, Japan) was 
employed during the CT imaging (Fig. 1A). The resul-
tant Digital Imaging and Communications in Medicine 
(DICOM) data were evaluated with ImageJ (National 
Institute of Health, Bethesda, MD). BMD was measured 
using quantitative computed tomography (QCT). Re-
gions of interest (ROI) were drawn on axial images that 
passed through the mental foramen (Fig. 1B). The ROI 
were drawn so that they only included spongiotic bone. 
In order to exclude soft tissue, bone was defi ned as tis-
sue that exhibited attenuation values of ≥ 300 Hounsfi eld 
units.
Statistical analysis
Statistical analyses were performed using Excel 2010 
(Microsoft, Redmond, WA).  
 The correlation between control, ARONJ (healing) 
and ARONJ (non-healing) groups was calculated using 
the Tukey-Kramer test or Steel-Dwass test. Student’s t-
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B A 
Fig. 1. Use of the calibration phantom.
A: Photograph showing the calibration phantom. B: ROI (arrow) were drawn on an axial image passing through the mental foramen. The 
ROI were drawn so that they only included spongiotic bone. CT image showing the calibration phantom (arrowhead). CT, computed to-
mography; ROI, regions of interest.
test was used for comparisons between pairs of categori-
cal variables. P-values of < 0.05 were considered to be 
statistically signifi cant.
RESULTS
The control, ARONJ (healing), and ARONJ (non-heal-
ing) groups contained 24, 15, and 17 patients, respec-
tively. The mean ages of the control, ARONJ (healing) 
and ARONJ (non-healing) groups were 67.6 years (range, 
48–83 years), 75.1 years (range, 61–93 years) and 69.0 
years (range, 40–80 years), respectively. No signifi cant 
difference was detected among the mean ages of 3 
Table 1. Characteristics of the 32 patients with ARONJ and the 24 control patients
Control (n = 24)
ARONJ (n = 32)
Healing (n = 15) No healing (n = 17)
Gender
Male 1 3 8
Female 23 12 9
Mean age 67.6 y (48–83 y) 75.1 y (61–93 y) 69.0 y (40–80 y)
Disease
Bony metastasis 2 1 11
Osteoporosis 20 12 3
Multiple myeloma 0 1 1
Other 2 1 2
Administration method
Intravenous 2 2 11
Oral 22 13 6
Type of drug
Bisphosphonate 24 15 16
Denosumab 0 0 1
ARONJ, anti-resorptive agent-related osteonecrosis of the jaw; y, year(s).
groups. The patients’ other characteristics are shown in 
Table 1. In addition, 4 patients (14.3%) that underwent 
tooth extraction subsequently developed ARONJ. These 
patients were not included in the control group. The 
mandibular BMD values of the 4 patients were 504 mg/
mL, 564 mg/mL, 519 mg/mL and 412 mg/mL, respec-
tively. 2 (50.0%) of 4 patients were healing.
Patients’ serum NTX and BAP levels
The mean serum NTX levels (± standard deviation) 
of the control and ARONJ groups were 9.8 ± 1.1 nmol 
bone collagen equivalents (BCE)/L and 12.8 ± 3.2 nmol 
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BCE/L, respectively. The mean serum BAP levels of the 
control and ARONJ groups were 17.9 ± 1.8 U/L and 21.8 
± 8.5 U/L, respectively (Fig. 2). The differences between 
the two groups were not significant.
Control ARONJ
NTX (nmol BCE/L) 
(n = 24) (n = 32)
BAP (U/L) 
Control ARONJ
(n = 24) (n = 32)
NTX (nmol BCE/L) BAP (U/ ) 
Control ARONJ 
(healing) 
ARONJ 
(no healing)
(n (n = 24)  = 15) (n = 17)
Control ARONJ 
(healing) 
( (n (n = 24) n = 15) = 17)
ARONJ 
(no healing)
*** 
** 
Fig. 3. Levels of systemic markers of bone turnover according to 
the outcome of ARONJ.
The left figure shows serum NTX levels and the right figure shows 
serum BAP levels. The correlation between control, ARONJ 
(healing) and ARONJ (non-healing) groups was calculated using 
the Tukey-Kramer test. The NTX levels of ARONJ (no healing) 
groups were significantly higher than that of the control group and 
ARONJ (healing) group (**P < 0.01,***P < 0.05). However, there 
was no significant difference among the BAP levels of the control, 
ARONJ (healing) and ARONJ (no healing) groups. ARONJ, anti-
resorptive agent-related osteonecrosis of the jaw; BAP, bone al-
kaline phosphatase; NTX, cross-linked N-terminal telopeptide of 
type I collagen.
Fig. 2. The levels of systemic markers of bone turnover in the con-
trol and ARONJ groups.
The left figure shows serum NTX levels, and the right figure 
shows serum BAP levels. The correlation between control and 
ARONJ group was calculated using the Student’s t-test. No sig-
nificant differences were detected between the local mandibular 
statuses of the two groups with regard to NTX or BAP. ARONJ, 
anti-resorptive agent-related osteonecrosis of the jaw; BAP, bone 
alkaline phosphatase; NTX, cross-linked N-terminal telopeptide 
of type I collagen.
 In addition, the mean NTX levels of the ARONJ 
(healing) and ARONJ (non-healing) groups were 10.4 
± 1.4 nmol BCE/L and 14.8 ± 3.9 nmol BCE/L, respec-
tively, and the mean BAP levels of the ARONJ (healing) 
and ARONJ (non-healing) groups were 18.3 ± 4.2 U/
L and 24.8 ± 10.9 U/L, respectively (Fig. 3). The NTX 
levels of non-healing ARONJ groups were significantly 
higher than that of control group (P < 0.01) and similarly 
higher than that of healing ARONJ groups (P < 0.05). 
However, there were no significant differences among 
the BAP levels of the control, ARONJ (healing) and 
ARONJ (non-healing) groups.
Levels of systemic markers of bone turnover ac-
cording to the clinical stage of ARONJ
There were 6, 19, and 7 patients with stage 1, 2 and 3 
ARONJ, respectively. The mean NTX levels of the stage 
1, 2 and 3 patients were 11.3 ± 3.1 nmol BCE/L, 11.6 ± 
1.4 nmol BCE/L and 16.7 ± 5.4 nmol BCE/L, respec-
tively. The mean BAP levels of the stage 1, 2, and 3 
patients were 28.2 ± 14.4 U/L, 18.7 ± 4.7 U/L and 24.4 ± 
10.8 U/L, respectively (Fig. 4). No significant difference 
was detected among the systemic marker levels of the 
control, stage 1, stage 2, and stage 3 patients.
Control
(n = 24)
Stage 1 Stage 2 Stage 3 
(n = 6) (n = 19) (n = 7)
NTX (nmol BCE/L) BAP (U/ ) 
Control
(n = 24)
Stage 1 Stage 2 Stage 3 
(n = 6) (n = 19) (n = 7)
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Fig. 4. Levels of systemic markers of bone turnover according to 
the clinical stage of ARONJ.
The left figure shows serum NTX levels and the right figure shows 
serum BAP levels. The correlation between control and each 
clinical stage of ARONJ was calculated using the Steel-Dwass 
test. No significant differences were detected among the 4 groups. 
ARONJ, anti-resorptive agent-related osteonecrosis of the jaw; 
BAP, bone alkaline phosphatase; NTX, cross-linked N-terminal 
telopeptide of type I collagen.
Patients’ mandibular BMD values 
The mandibular BMD values of the control and ARONJ 
groups are shown in Fig. 5. The mean BMD values of 
the control and ARONJ groups were 403.5 ± 31.7 mg/
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mL and 522.4 ± 58.7 mg/mL, respectively. The mean 
mandibular BMD value of the ARONJ group was signif-
icantly higher than that of the control group (P < 0.001).
 In addition, the mandibular BMD values of the 
ARONJ (healing) and ARONJ (non-healing) groups are 
shown in Fig. 6. The mean mandibular BMD values of 
the ARONJ (healing) and ARONJ (non-healing) groups 
were 534.1 ± 67.9 mg/mL and 512.2 ± 51.1 mg/mL, 
respectively. The BMD values of both groups were sig-
nificantly higher than that of the control group (P < 0.01). 
However, there was no significant difference between 
the BMD values of the ARONJ (healing) and ARONJ 
(non-healing) groups.
Mandibular BMD values according to the clinical 
stage of ARONJ
The mean BMD values of the stage 1, 2 and 3 patients 
were 522.7 ± 45.2 mg/mL, 522.7 ± 67.9 mg/mL and 
522.0 ± 51.4 mg/mL, respectively (Fig. 7).
 The BMD values of all ARONJ stages were signifi-
cantly higher than that of the control group (P < 0.05), 
but no significant differences were detected among the 
BMD values of the stage 1, 2 and 3 patients.
Control ARONJ
BMD (mg/mL) 
* 
(n = 24) (n = 32)
Control ARONJ (healing) ARONJ (no healing)
BMD (mg/mL) 
** 
** 
(n = 24) (n = 15) (n = 17)
Control
BMD (mg/mL) 
** 
*** 
(n = 24)
Stage 1 Stage 2 Stage 3 
(n = 6) (n = 19) (n = 7)
*** 
Fig. 5. The correlation BMD values between control and ARONJ 
group was calculated using the Student’s t-test.
The mean BMD value of the ARONJ group was greater than that 
of the control (*P < 0.001). ARONJ, anti-resorptive agent-related 
osteonecrosis of the jaw; BMD, bone mineral density.
Fig. 7. The correlation BMD values according to the clinical stage 
of ARONJ was calculated using the Steel-Dwass test.
The BMD values of the patients with each clinical stage of 
ARONJ were significantly higher than that of the control group 
(**P < 0.01,***P < 0.05). However, the BMD values of the stage 
1, 2 and 3 ARONJ patients did not differ significantly. ARONJ, 
anti-resorptive agent-related osteonecrosis of the jaw; BMD, bone 
mineral density.
Fig. 6. The correlation BMD values between control, ARONJ 
(healing) and ARONJ (non-healing) groups was calculated using 
the Tukey-Kramer test.
The BMD values of the ARONJ (healing) and ARONJ (non-heal-
ing) groups were higher than those of the control group (*P  < 0.01). 
In contrast, no significant difference was detected between the 
BMD values of the ARONJ (healing) and ARONJ (non-healing) 
groups. ARONJ, anti-resorptive agent-related osteonecrosis of the 
jaw; BMD, bone mineral density.
DISCUSSION
The first case of ARONJ was reported over a decade 
ago,17 but the pathophysiology of the disease has not 
been fully elucidated. Various hypotheses have been 
proposed to explain the exclusive localization of ARONJ 
in the jaws, including altered bone remodeling or the 
excessive suppression of bone resorption, a reduction in 
blood supply, continuous dentoalveolar trauma, the sup-
pression of innate or acquired immunity, vitamin D defi-
ciency, soft tissue bisphosphonate toxicity, inflammation 
and infection.30–38
 Patients that are treated with anti-resorptive agents 
and undergo dentoalveolar surgery are at least 7 times 
more likely to develop ARONJ than patients who do 
not undergo dentoalveolar surgery. However, patients 
who receive anti-resorptive agents and do not develop 
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ARONJ after undergoing dentoalveolar surgery remains 
unclear.39 The present study is the first to examine 
ARONJ risk prediction using such patients as a control 
group.
 The imaging findings of ARONJ are similar to those 
of common osteomyelitis of the jaw, and there is es-
sentially no difference between the two conditions.40–42 
In addition, the hematological and histopathological 
findings of the two conditions are also similar. Thus, 
ARONJ is primarily diagnosed based on its clinical 
findings, but radiographic imaging is essential for de-
termining the extent of the disease, diagnosing ARONJ 
in its early stages, identifying metastatic disease, and 
excluding fractures.42, 43
 The main characteristic of ARONJ is that it is in-
tractable. In this study, we noticed that many ARONJ 
patients with bone metastasis does not show a healing 
tendency especially when they receive intravenous anti-
resorptive agents. 
 Furthermore, patients with cancer generally have a 
weakened immune system, so we thought that intracta-
bility was promoted by declining immunity. This makes 
early detection very important. Various methods for 
early diagnosis of ARONJ have been examined.
 A number of studies have investigated ARONJ risk 
prediction based on serum NTX levels.40, 41, 44–46 How-
ever, the utility of systemic markers of bone turnover for 
assessing the risk of jaw necrosis has not been validated. 
This study was not able to validate its utility either. 
Markers of bone turnover are influenced by both local 
and systemic factors. Moreover, NTX levels increase in 
patients who did not show any sign of healing. Gener-
ally, bone turnover is inhibited by anti-resorptive agents. 
We speculate that the systemic factors affecting such 
markers might include circadian rhythms, dietary ef-
fects, systemic bone disease and bone metastases. There-
fore, systemic markers of the effects of bisphosphonates 
might not be indicative of the local bone changes that di-
rectly influence the risk of ARONJ or factors such as the 
regional toxic effects of bisphosphonate on bone quality 
and local circulation.47
 Radiographic imaging is an effective method for 
diagnosing ARONJ as the BMD of the jaws is affected 
less by systemic factors than by bone turnover. In pa-
tients that have been treated with anti-resorptive agents, 
CT images of the mandible show osteosclerotic changes. 
Thus, the mandibular bone might reflect the effects 
of drugs to a greater extent than other bones. Several 
reports have evaluated the appearance of ARONJ on 
different imaging modalities.48–61 However, there is no 
established method for diagnosing the condition.
 We were concerned that our results might be af-
fected by inter-reader variability, such as that caused by 
vagueness regarding the location of the measurement 
site or the use of ROI that were too small. Therefore, 
we developed a measurement method to decrease inter-
reader variability. The mental foramen is a characteristic 
anatomical feature of the mandible and is located below 
the roots of the teeth. Thus, an axial CT section that 
passed through the mental foramen was chosen, and the 
ROI was drawn so that it included the mental foramen. 
This approach makes sense as it has been reported that 
ARONJ most commonly affects sites in the mandibular 
molar region.56, 60 In addition, we minimized the ef-
fects of inflammation caused by ARONJ or periodontal 
disease on our findings by obtaining measurements in 
the anterior mandible. In a pilot study, the results we ob-
tained in the anterior mandible were more accurate than 
those obtained in the mandibular molar region (data not 
shown).
 In the present study, the mandibular BMD of the 
ARONJ group was significantly greater than that of the 
control group. The 4 patients that developed ARONJ 
after undergoing tooth extraction exhibited a high mean 
pre-tooth extraction BMD (499 mg/mL), and 3 of these 
4 patients displayed mandibular BMD values of ≥ 500 
mg/mL. Our results support the findings of a previous 
study48, 50 in which the ARONJ group exhibited higher 
BMD values than the control group. The control patients 
in the present study received an anti-resorptive agent be-
fore tooth extraction and did not develop ARONJ. This 
study demonstrated that patients with high BMD values 
are at a high risk for ARONJ. These results suggest that 
promotion of osteosclerosis of the jaw mainly due to 
treatment with systemic anti-resorptive agents. ARONJ 
may result from a decreased blood flow in the cancellous 
bone.
 We did not detect a significant difference between 
the BMD values of patients with different stages of 
ARONJ or between those of the healing and non-healing 
groups, which agrees with the findings of previous stud-
ies.48, 50 In addition, our findings are similar to those 
seen in cases of stage 1 to 3 ARONJ involving exposed 
bone. 
 Bone turnover occurs at a faster rate in cancellous 
bone than in cortical bone; thus, the BMD of cancellous 
bone is a good indicator of bone turnover and might of-
fer a simple, quantitative means of detecting ARONJ 
early. Therefore, we examined cancellous bone in the 
present study. However, we were not able to detect 
the relationship between BMD and several stages of 
ARONJ. Thus, changes associated with the stages of os-
teosclerotic responses might not be detectable on imag-
ing scans.63, 64 Further studies are needed to examine the 
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pharmacokinetics of anti-resorptive agents and the local 
changes that they induce during the stages of ARONJ.
 In conclusion, patients that had developed ARONJ 
after receiving systemic anti-resorptive agents exhibited 
higher mandibular BMD values than patients who had 
been treated with systemic anti-resorptive agents without 
developing ARONJ. These results suggest that increases 
in mandibular BMD are associated with ARONJ. Fur-
thermore, mandibular BMD might be a useful marker 
for predicting the risk of ARONJ prior to tooth extrac-
tion or jaw surgery in patients that have been treated 
with anti-resorptive agents. Accordingly, mandibular 
BMD could be a useful clinical parameter for aiding risk 
assessment and guiding therapeutic decision-making.
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